Oric Pharmaceuticals/ORIC

$9.76

3.28%
-
1D1W1MYTD1YMAX

About Oric Pharmaceuticals

ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in improving patients' lives by overcoming resistance in cancer. It is developing a pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. Its clinical-stage product candidates include ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers, ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens.

Ticker

ORIC

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Jacob Chacko

Employees

100

Headquarters

South san francisco, United States

ORIC Metrics

BasicAdvanced
$642.77M
Market cap
-
P/E ratio
-$1.97
EPS
1.15
Beta
-
Dividend rate
$642.77M
1.14897
$16.65
$4.89
607.25K
10.392
-40.34%
-45.11%
-43.47%
2.336
2.868
12.37%

What the Analysts think about ORIC

Analyst Ratings

Majority rating from 9 analysts.
Buy

Price Targets

Average projection from 7 analysts.
96.11% upside
High $25.00
Low $15.00
$9.76
Current price
$19.14
Average price target

ORIC Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
-
Net income
$-28.3M
11.42%
Profit margin
0%
-

ORIC Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 0.73%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.53
-$0.50
-$0.44
-$0.49
-
Expected
-$0.54
-$0.57
-$0.46
-$0.49
-$0.43
Surprise
-1.88%
-12.15%
-4.74%
0.73%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Oric Pharmaceuticals stock?

Oric Pharmaceuticals (ORIC) has a market cap of $642.77M as of April 17, 2024.

What is the P/E ratio for Oric Pharmaceuticals stock?

The price to earnings (P/E) ratio for Oric Pharmaceuticals (ORIC) stock is 0 as of April 17, 2024.

Does Oric Pharmaceuticals stock pay dividends?

No, Oric Pharmaceuticals (ORIC) stock does not pay dividends to its shareholders as of April 17, 2024.

When is the next Oric Pharmaceuticals dividend payment date?

Oric Pharmaceuticals (ORIC) stock does not pay dividends to its shareholders.

What is the beta indicator for Oric Pharmaceuticals?

Oric Pharmaceuticals (ORIC) has a beta rating of 1.15. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Oric Pharmaceuticals stock price target?

The target price for Oric Pharmaceuticals (ORIC) stock is $19.14, which is 96.11% above the current price of $9.76. This is an average based on projections from 7 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Oric Pharmaceuticals stock

Buy or sell Oric Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing